13 Going On 50: Pfizer Seeks Adult Indication For Prevnar
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee might closely scrutinize the requested indication for the 13-valent pneumococcal conjugate vaccine for adults age 50 and up; it is now indicated for children under six years old.
You may also be interested in...
Pfizer Anticipates Prevnar 13 For Older Adults Will Get Advisory Review In September
After the advisory committee, FDA would have one month to complete its review before the next ACIP meeting.
Pfizer Anticipates Prevnar 13 For Older Adults Will Get Advisory Review In September
After the advisory committee, FDA would have one month to complete its review before the next ACIP meeting.
In Advance Of HSV-2 Vaccine Trials, Genocea Taps Investors For $35 Million
The four-year-old antigen discovery platform developer has added corporate VCs, seeking to broaden its eventual exit opportunities.